Array BioPharma names Carrie S. Cox chair of its board of directors

Array BioPharma names Carrie S. Cox chair of its board of directors

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) today announced Carrie S. Cox has been named chair of its board of directors effective immediately. Cox has been appointed to the Audit and... Read More

Tuesday August 14, 2018 0 comments Tags: Boulder, Array BioPharma, Carrie Cox, Ron Squarer

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

Array BioPharma colorectal cancer drugs receive Breakthrough Therapy Designation from FDA

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) today announced it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI),... Read More

Tuesday August 7, 2018 0 comments Tags: Boulder, Array BioPharma, Victor Sandor, FDA

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

Array BioPharma: European Medicines Agency recommends approval of melanoma cancer drug

BOULDER -- Array BioPharma Inc. (NASDAQ: ARRY) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending... Read More

Monday July 30, 2018 0 comments Tags: Boulder, Array BioPharma, Ron Squarer

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

Array BioPharma: National Comprehensive Cancer Network, FDA OKs drug combo for melanoma

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) announced that the National Comprehensive Cancer Network (NCCN) has updated the Clinical Practice Guidelines in Oncology for Melanoma to include... Read More

Monday July 16, 2018 0 comments Tags: Boulder, Array BioPharma, melanoma, Ron Squarer, FDA

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

Array BioPharma announces FDA approval of encorafenib and binimetinib cancer drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) announced the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI(encorafenib) capsules in combination with MEKTOVI(binimetinib)tablets... Read More

Thursday June 28, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Ron Squarer

Array BioPharma reports positive survival results for melanoma drugs

Array BioPharma reports positive survival results for melanoma drugs

BOULDER -- Array BioPharma Inc . (Nasdaq: ARRY) andFrance-based Pierre Fabreannounced results of a study of overall survival in patients with BRAF -mutant melanoma, indicating that treatment with... Read More

Wednesday February 7, 2018 0 comments Tags: Boulder, Array BioPharma, encorafenib, binimetinib, Victor Sandor

Array’s triplet drug combination found effective for colorectal cancer treatment

Array’s triplet drug combination found effective for colorectal cancer treatment

BOULDER -- Array BioPharma Inc. (Nasdaq: ARRY) and Pierre Fabre today announced updated results from the 30 patient safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet... Read More

Monday January 22, 2018 0 comments Tags: Boulder, Array BioPharma, binimetinib, encorafenib, cetuximab, Pierre Fabre

Array BioPharma to collaborate with Pfizer on clinical drug trials

Array BioPharma to collaborate with Pfizer on clinical drug trials

BOULDER -- Array BioPharma (Nasdaq: ARRY) today announced it has entered into a clinical trial collaboration agreement with Pfizer to investigate the safety and efficacy of several novel... Read More

Tuesday December 19, 2017 0 comments Tags: Boulder, Array BioPharma, Pfizer, Ron Squarer